"Official medicines" is the best online drugstore.World’s leading meds delivered to your door – and you don’t even need a prescription! Only certified, first class drugs on offer! Buy more and spend less with our great discount system. The meds you need, reliable and hassle free! Top products of top brands.The only pharmacy shop you will ever need! Approved drugs available without prescription. Best deals, unmatched service and shipping. 100% safe! |
| (tran-DOE-lah-prill) |
| Mavik |
| Class: Antihypertensive/ACE inhibitor |
Action Reduces the formation of the vasopressor hormone angiotensin II by inhibiting angiotensin converting enzyme (ACE). Results in decreased BP, reduced sodium reabsorption and potassium retention.
Indications Hypertension: Treatment of hypertension either alone or in combination with other antihypertensive drugs. Heart Failure Post-MI/Left-Ventricular Dysfunction Post-MI: For stable patients who have evidene of left-ventricular systolic dysfunction (dentified by wall motion abnormalities) or who are symptomatic from CHF within the first few days after sustaining acute MI.
Contraindications Hypersensitivity or history of angioedema with any ACE inhibitor.
Hypertension
ADULTS: PO 1–2 mg once daily initially with usual maintenance doses of 2–4 mg once daily.
Heart failure post-MI/Left-ventricular dysfunction post-MI
ADULTS: PO 1 mg/day. Following initial dose, titrate patients (as tolerated) toward a target dosage of 4 mg/day. RENAL/HEPATIC FUNCTION IMPAIRMENT: PO For patients with a creatinine clearance < 30 ml/min or with hepatic cirrhosis, starting dosage is 0.5 mg/day.
Allopurinol: Greater risk of hypersensitivity possible with coadministration. Diuretics: Possible hypotensive effect. Use lower starting doses. Potassium supplements or potassium-sparing drugs: May increase serum potassium levels. Lithium salts: Increased serum lithium levels and increased risk of lithium toxicity.
Lab Test Interferences None well documented.
CNS: Dizziness; headache; fatigue. GI: Diarrhea. META: Hyperkalemia. RESP: Cough (especially in females). OTHER: Angioedema; increased serum creatinine; BUN.
Pregnancy: Category D. (second and third trimester;) Category C. (First trimester) void use in nursing women if possible. Elderly: Reduce doses may be needed. Angioedema: Use with extreme caution in patients with hereditary angioedema. Lactation: Undetermined. Renal impairment: Reduce dosage. Decreases in renal function may occur if renal function is dependent on the renin-angiotensin system; patients with renal artery stenosis may experience acute renal failure. Hypotension/first-dose effect: Hypotension may occur during initiation of therapy, especially in patients with severe salt or volume depletion or those with CHF. Anaphylactoid teactions: Angioedema and anaphylactoid reactions are rarely reported but are potentially life-threatening. Hepatic failure: May occur. Discontinue drug if patient develops jaundice. Neutropenia or agranulocytosis: May occur; risk appears greater in patients with renal dysfunction, heart failure or immunosuppression. Periodically monitor WBC counts in these patients.
| PATIENT CARE CONSIDERATIONS |
|
|
||||
Popularity: 1% [?]
RSS feed for comments on this post · TrackBack URI
Leave a reply